Literature DB >> 11082141

Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.

P M Okin1, R B Devereux, S Jern, S E Kjeldsen, S Julius, B Dahlöf.   

Abstract

The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of atenolol on the reduction of cardiovascular morbidity and mortality. A total of 9194 patients with hypertension and ECG left ventricular hypertrophy (LVH) by Cornell voltage-duration product and/or Sokolow-Lyon voltage criteria were enrolled in the study, with baseline clinical and ECG data available in 8785 patients (54% women; mean age, 67+/-7 years). ECG LVH by Cornell voltage-duration product criteria was present in 5791 patients (65.9%) and by Sokolow-Lyon voltage in 2025 patients (23.1%). Compared with patients without ECG LVH by Cornell voltage-duration product criteria, patients with ECG LVH by this method were older; more obese; more likely to be female, white, and to have never smoked; more likely to be diabetic and have angina; and had slightly higher systolic, diastolic, and pulse blood pressures. In contrast, patients with ECG LVH by Sokolow-Lyon criteria were slightly younger; less obese; more likely to be male, black, and current smokers; less likely to have diabetes; more likely to have angina and a history of cerebrovascular disease; and had higher systolic and pulse blood pressure but slightly lower diastolic blood pressure than patients without ECG LVH by this method. By use of multivariate logistic regression analyses, presence of ECG LVH by Cornell voltage-duration product criteria was predominantly associated with higher body mass index, increased age, and female gender, whereas presence of ECG LVH by Sokolow-Lyon voltage criteria was predominantly related to lower body mass index, male gender, and black race. Thus, hypertensive patients who meet Cornell product and Sokolow-Lyon voltage criteria are associated with different, but potentially equally adverse, risk factor profiles.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082141     DOI: 10.1161/01.hyp.36.5.766

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

1.  Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Authors:  G Boner; M E Cooper; K McCarroll; B M Brenner; D de Zeeuw; P R Kowey; S Shahinfar; T Dickson; R S Crow; H-H Parving
Journal:  Diabetologia       Date:  2005-08-05       Impact factor: 10.122

2.  What can genetic studies of left ventricular mass tell us?

Authors:  Christopher Newton-Cheh
Journal:  Circ Cardiovasc Genet       Date:  2011-12

3.  The early repolarization pattern in the general population: clinical correlates and heritability.

Authors:  Peter A Noseworthy; Jani T Tikkanen; Kimmo Porthan; Lasse Oikarinen; Arto Pietilä; Kennet Harald; Gina M Peloso; Faisal M Merchant; Antti Jula; Heikki Väänänen; Shih-Jen Hwang; Christopher J O'Donnell; Veikko Salomaa; Christopher Newton-Cheh; Heikki V Huikuri
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

4.  Determinants and prognostic significance of electrocardiographic left ventricular hypertrophy criteria in chronic kidney disease.

Authors:  Rajiv Agarwal; Robert P Light
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-18       Impact factor: 8.237

Review 5.  Left ventricular hypertrophy in association with cognitive impairment: a systematic review and meta-analysis.

Authors:  Marios K Georgakis; Andreas Synetos; Constantinos Mihas; Maria A Karalexi; Dimitrios Tousoulis; Sudha Seshadri; Eleni Th Petridou
Journal:  Hypertens Res       Date:  2017-02-16       Impact factor: 3.872

6.  Accuracy of advanced versus strictly conventional 12-lead ECG for detection and screening of coronary artery disease, left ventricular hypertrophy and left ventricular systolic dysfunction.

Authors:  Todd T Schlegel; Walter B Kulecz; Alan H Feiveson; E Carl Greco; Jude L DePalma; Vito Starc; Bojan Vrtovec; M Atiar Rahman; Michael W Bungo; Matthew J Hayat; Terry Bauch; Reynolds Delgado; Stafford G Warren; Tulio Núñez-Medina; Rubén Medina; Diego Jugo; Håkan Arheden; Olle Pahlm
Journal:  BMC Cardiovasc Disord       Date:  2010-06-16       Impact factor: 2.298

7.  Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study.

Authors:  Vivencio Barrios; Carlos Escobar; Alberto Calderón; Sara Barrios; Josefa Navarro-Cid; Elena Ferrer; Rocio Echarri
Journal:  Heart Vessels       Date:  2010-01-21       Impact factor: 2.037

8.  [Interobserver agreement on electrocardiographic diagnosis of left ventricular hypertrophy in hypertensive patients in Andalusia. PREHVIA study].

Authors:  Enrique Martín-Rioboó; Amador López Granados; Luis Cea Calvo; Luis Angel Pérula De Torres; Emilio García Criado; Manuel P Anguita Sánchez; Lisardo García Matarín; Rafael Molina Díaz; Tomas Ureña Fernández
Journal:  Aten Primaria       Date:  2009-04-26       Impact factor: 1.137

9.  Cornell product left ventricular hypertrophy in electrocardiogram and the risk of stroke in a general population.

Authors:  Joji Ishikawa; Shizukiyo Ishikawa; Tomoyuki Kabutoya; Tadao Gotoh; Kazunori Kayaba; Joseph E Schwartz; Thomas G Pickering; Kazuyuki Shimada; Kazuomi Kario
Journal:  Hypertension       Date:  2008-11-17       Impact factor: 10.190

10.  Correlation relationship assessment between left ventricular hypertrophy voltage criteria and body mass index in 41,806 Swiss conscripts.

Authors:  Roger Abächerli; Lingchuan Zhou; Johann-Jakob Schmid; Richard Kobza; Bernhard Niggli; Franz Frey; Paul Erne
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-10       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.